SGLT2 inhibitor, a kind of hypoglycemic drug, whose mechanism is to suppress glucose reabsorption in proximal renal tubules in the kidney to promote the excretion of glucose, has been demonstrated to have a positive effect on our cardiovascular system and reduce the risk of suffering from cardiovascular events. In this review, we will focus on four aspects to elaborate on its mechanism. First: diuresis and electrolytes, second: blood pressure, hormone, and nerve, third: regulating lipid metabolism, and the last: the direct effect on cardiomyocytes. This paper presents some puzzles of different mechanisms, aiming for waiting to be answered in later research
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
peer reviewedSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering ...
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal ...
Diabetes is a global epidemic and a leading cause of death with more than 422 million patients world...
Heart failure (HF) continues to be a serious public health challenge despite significant advancement...
Diabetes is a growing epidemic worldwide characterized by an elevated concentration of blood glucose...
This review provides mechanistic insight in the pleiotropic effects of sodium-glucose transporter-2 ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that reduce blood glucose...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-...
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
peer reviewedSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering ...
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal ...
Diabetes is a global epidemic and a leading cause of death with more than 422 million patients world...
Heart failure (HF) continues to be a serious public health challenge despite significant advancement...
Diabetes is a growing epidemic worldwide characterized by an elevated concentration of blood glucose...
This review provides mechanistic insight in the pleiotropic effects of sodium-glucose transporter-2 ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that reduce blood glucose...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-...
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
The mechanisms of cardiovascular and renal protection observed in clinical trials of SGLT2 inhibitor...
peer reviewedSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering ...